Jackson Square Capital LLC acquired a new position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 72,456 shares of the company's stock, valued at approximately $1,596,000.
Several other large investors have also recently added to or reduced their stakes in the business. Quarry LP bought a new position in shares of Cellebrite DI in the third quarter worth $27,000. Point72 Asia Singapore Pte. Ltd. grew its position in Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company's stock valued at $33,000 after buying an additional 1,017 shares in the last quarter. Advisors Asset Management Inc. increased its stake in Cellebrite DI by 130.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock valued at $52,000 after buying an additional 1,742 shares during the period. Pathway Financial Advisers LLC raised its position in shares of Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock worth $74,000 after buying an additional 4,118 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new stake in shares of Cellebrite DI in the 2nd quarter worth approximately $71,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on CLBT shares. Needham & Company LLC boosted their target price on Cellebrite DI from $17.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price objective on Cellebrite DI from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Monday, December 16th. Craig Hallum raised their target price on Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Finally, TD Cowen boosted their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI has a consensus rating of "Buy" and an average price target of $20.57.
Check Out Our Latest Research Report on CLBT
Cellebrite DI Stock Performance
Shares of NASDAQ:CLBT traded down $0.20 during midday trading on Friday, reaching $22.78. The company had a trading volume of 1,221,391 shares, compared to its average volume of 879,357. The company has a fifty day simple moving average of $20.76 and a two-hundred day simple moving average of $17.64. The firm has a market cap of $4.69 billion, a price-to-earnings ratio of -14.70, a price-to-earnings-growth ratio of 3.18 and a beta of 1.46. Cellebrite DI Ltd. has a 1-year low of $8.23 and a 1-year high of $23.50.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business had revenue of $106.90 million for the quarter, compared to analyst estimates of $102.06 million. During the same quarter in the previous year, the business earned $0.09 earnings per share. The firm's revenue was up 27.0% compared to the same quarter last year. Analysts expect that Cellebrite DI Ltd. will post 0.32 EPS for the current year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
